Baseline patient characteristics
| Variable . | Deferasirox (n = 98) . | DFO (n = 99) . | All patients (n = 197) . |
|---|---|---|---|
| β-thalassemia major, n (%) | 98 (100) | 99 (100) | 197 (100) |
| Age, y | 19.9 ± 6.5 | 19.7 ± 6.3 | 19.8 ± 6.4 |
| Age range, y | 10.0-39.0 | 10.0-40.0 | 10.0-40.0 |
| Male:female, n | 58:40 | 57:42 | 115:82 |
| Race, n (%) | |||
| White | 59 (60.2) | 59 (59.6) | 118 (59.9) |
| Black | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Asian | 38 (38.8) | 40 (40.4) | 78 (39.6) |
| Other | 1 (1.0) | 0 (0.0) | 1 (0.5) |
| Hepatitis status, n (%) | |||
| Hepatitis B | 1 (1.0) | 2 (2.0) | 3 (1.5) |
| Hepatitis C | 22 (22.4) | 19 (19.2) | 41 (20.8) |
| Hepatitis B and C | 0 (0.0) | 2 (2.0) | 2 (1.0) |
| No hepatitis | 75 (76.5) | 80 (80.8) | 155 (78.7) |
| Time since start of blood transfusions, y | 19.3 ± 6.4 | 18.4 ± 6.2 | 18.8 ± 6.3 |
| Total number of blood transfusions received | 315.6 | 294.8 | 305.3 |
| Previous chelation therapy, n (%) | 96 (100) | 91 (100) | 187 (100) |
| DFO | 41 (42.7) | 39 (42.9) | 80 (42.8) |
| Deferiprone | 9 (9.4) | 5 (5.5) | 14 (7.5) |
| DFO + deferiprone | 21 (21.9) | 21 (23.1) | 42 (22.5) |
| Deferasirox | 18 (18.8) | 23 (25.3) | 41 (21.9) |
| Other† | 7 (7.3) | 3 (3.3) | 10 (5.3) |
| Time since start of first chelation therapy, y | 14.0 ± 7.0 | 14.3 ± 7.2 | 14.2 ± 7.1 |
| Myocardial T2* categories, n (%) | |||
| 6 to <10 ms | 33 (33.7) | 32 (32.3) | 65 (33.0) |
| 10 to ≤20 ms | 65 (66.3) | 67 (67.7) | 132 (67.0) |
| LVEF, n (%)‡ | |||
| <LLN by Westwood§ | 11 (12.1) | 10 (12.3) | 21 (12.2) |
| ≥LLN by Westwood§ | 80 (87.9) | 71 (87.7) | 151 (87.8) |
| LIC, mg Fe/g dw‡ | 29.8 ± 17.5 | 30.3 ± 17.9 | 30.0 ± 17.7 |
| LIC categories, n (%)‡ | |||
| LIC < 7 mg Fe/g dw | 11 (12.1) | 8 (9.9) | 19 (11.0) |
| LIC 7 to <15 mg Fe/g dw | 14 (15.4) | 14 (17.3) | 28 (16.3) |
| LIC ≥ 15 mg Fe/g dw | 66 (72.5) | 59 (72.8) | 125 (72.7) |
| Median serum ferritin (range), ng/mL‡ | 5062 (613-15 331) | 4684 (677-13 342) | 4878 (613-15 331) |
| Variable . | Deferasirox (n = 98) . | DFO (n = 99) . | All patients (n = 197) . |
|---|---|---|---|
| β-thalassemia major, n (%) | 98 (100) | 99 (100) | 197 (100) |
| Age, y | 19.9 ± 6.5 | 19.7 ± 6.3 | 19.8 ± 6.4 |
| Age range, y | 10.0-39.0 | 10.0-40.0 | 10.0-40.0 |
| Male:female, n | 58:40 | 57:42 | 115:82 |
| Race, n (%) | |||
| White | 59 (60.2) | 59 (59.6) | 118 (59.9) |
| Black | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Asian | 38 (38.8) | 40 (40.4) | 78 (39.6) |
| Other | 1 (1.0) | 0 (0.0) | 1 (0.5) |
| Hepatitis status, n (%) | |||
| Hepatitis B | 1 (1.0) | 2 (2.0) | 3 (1.5) |
| Hepatitis C | 22 (22.4) | 19 (19.2) | 41 (20.8) |
| Hepatitis B and C | 0 (0.0) | 2 (2.0) | 2 (1.0) |
| No hepatitis | 75 (76.5) | 80 (80.8) | 155 (78.7) |
| Time since start of blood transfusions, y | 19.3 ± 6.4 | 18.4 ± 6.2 | 18.8 ± 6.3 |
| Total number of blood transfusions received | 315.6 | 294.8 | 305.3 |
| Previous chelation therapy, n (%) | 96 (100) | 91 (100) | 187 (100) |
| DFO | 41 (42.7) | 39 (42.9) | 80 (42.8) |
| Deferiprone | 9 (9.4) | 5 (5.5) | 14 (7.5) |
| DFO + deferiprone | 21 (21.9) | 21 (23.1) | 42 (22.5) |
| Deferasirox | 18 (18.8) | 23 (25.3) | 41 (21.9) |
| Other† | 7 (7.3) | 3 (3.3) | 10 (5.3) |
| Time since start of first chelation therapy, y | 14.0 ± 7.0 | 14.3 ± 7.2 | 14.2 ± 7.1 |
| Myocardial T2* categories, n (%) | |||
| 6 to <10 ms | 33 (33.7) | 32 (32.3) | 65 (33.0) |
| 10 to ≤20 ms | 65 (66.3) | 67 (67.7) | 132 (67.0) |
| LVEF, n (%)‡ | |||
| <LLN by Westwood§ | 11 (12.1) | 10 (12.3) | 21 (12.2) |
| ≥LLN by Westwood§ | 80 (87.9) | 71 (87.7) | 151 (87.8) |
| LIC, mg Fe/g dw‡ | 29.8 ± 17.5 | 30.3 ± 17.9 | 30.0 ± 17.7 |
| LIC categories, n (%)‡ | |||
| LIC < 7 mg Fe/g dw | 11 (12.1) | 8 (9.9) | 19 (11.0) |
| LIC 7 to <15 mg Fe/g dw | 14 (15.4) | 14 (17.3) | 28 (16.3) |
| LIC ≥ 15 mg Fe/g dw | 66 (72.5) | 59 (72.8) | 125 (72.7) |
| Median serum ferritin (range), ng/mL‡ | 5062 (613-15 331) | 4684 (677-13 342) | 4878 (613-15 331) |